ProKidney Corp. Revenue and Competitors
Estimated Revenue & Valuation
- ProKidney Corp.'s estimated annual revenue is currently $18.9M per year.
- ProKidney Corp.'s estimated revenue per employee is $155,000
Employee Data
- ProKidney Corp. has 122 Employees.
- ProKidney Corp. grew their employee count by 54% last year.
ProKidney Corp.'s People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Legal Officer and Corporate Secretary | Reveal Email/Phone |
3 | CFO | Reveal Email/Phone |
4 | Chief People Officer | Reveal Email/Phone |
5 | Chief Operating Officer | Reveal Email/Phone |
6 | Chief Regulatory Officer | Reveal Email/Phone |
7 | Chief People Officer | Reveal Email/Phone |
8 | EVP, Clinical Development and Commercialization | Reveal Email/Phone |
9 | VP Clinical Operations | Reveal Email/Phone |
10 | VP Biometrics | Reveal Email/Phone |
ProKidney Corp. Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $11.2M | 72 | -13% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | $0.9M | 11 | -39% | N/A | N/A |
#6 | $1.7M | 11 | 10% | N/A | N/A |
#7 | $0.6M | 4 | -33% | N/A | N/A |
#8 | $4.8M | 31 | -6% | N/A | N/A |
#9 | $6.4M | 41 | 3% | N/A | N/A |
#10 | $4.2M | 27 | -18% | N/A | N/A |
What Is ProKidney Corp.?
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.
keywords:N/AN/A
Total Funding
122
Number of Employees
$18.9M
Revenue (est)
54%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $18.3M | 122 | -1% | N/A |
#2 | $30.5M | 124 | 8% | N/A |
#3 | N/A | 124 | N/A | N/A |
#4 | $21.8M | 136 | -34% | N/A |
#5 | $37M | 137 | 12% | N/A |